BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37973913)

  • 21. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
    Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
    Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Chakravarthi BVSK; Chandrashekar DS; Hodigere Balasubramanya SA; Robinson AD; Carskadon S; Rao U; Gordetsky J; Manne U; Netto GJ; Sudarshan S; Palanisamy N; Varambally S
    Prostate; 2018 Dec; 78(16):1311-1320. PubMed ID: 30051493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPT6 recruits SND1 to co-activate human telomerase reverse transcriptase to promote colon cancer progression.
    Diao C; Guo P; Yang W; Sun Y; Liao Y; Yan Y; Zhao A; Cai X; Hao J; Hu S; Yu W; Chen M; Wang R; Li W; Zuo Y; Pan J; Hua C; Lu X; Fan W; Zheng Z; Deng W; Luo G; Guo W
    Mol Oncol; 2021 Apr; 15(4):1180-1202. PubMed ID: 33305480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
    Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
    Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
    Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
    Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Small Inhibitors for Human Metadherin, an Oncoprotein, through
    Khattak AA; Ahmad A; Khattak HA; Irshad Khan MZ
    Curr Comput Aided Drug Des; 2023; 19(4):278-287. PubMed ID: 36627784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review).
    Jariwala N; Rajasekaran D; Srivastava J; Gredler R; Akiel MA; Robertson CL; Emdad L; Fisher PB; Sarkar D
    Int J Oncol; 2015 Feb; 46(2):465-73. PubMed ID: 25405367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
    Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
    PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation.
    Lorenzoni M; De Felice D; Beccaceci G; Di Donato G; Foletto V; Genovesi S; Bertossi A; Cambuli F; Lorenzin F; Savino A; Avalle L; Cimadamore A; Montironi R; Weber V; Carbone FG; Barbareschi M; Demichelis F; Romanel A; Poli V; Del Sal G; Julio MK; Gaspari M; Alaimo A; Lunardi A
    Cancer Lett; 2022 May; 534():215612. PubMed ID: 35259458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer.
    Shinde D; Albino D; Zoma M; Mutti A; Mapelli SN; Civenni G; Kokanovic A; Merulla J; Perez-Escuredo J; Costales P; Morìs F; Catapano CV; Carbone GM
    Eur Urol Oncol; 2019 Jul; 2(4):415-424. PubMed ID: 31277777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.
    Li F; Yuan Q; Di W; Xia X; Liu Z; Mao N; Li L; Li C; He J; Li Y; Guo W; Zhang X; Zhu Y; Aji R; Wang S; Tong X; Ji H; Chi P; Carver B; Wang Y; Chen Y; Gao D
    J Clin Invest; 2020 Nov; 130(11):5924-5941. PubMed ID: 32701507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Expression of Proto-Oncogene
    Khosh Kish E; Choudhry M; Gamallat Y; Buharideen SM; D D; Bismar TA
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Transcription Factor ERG Regulates Super-Enhancers Associated With an Endothelial-Specific Gene Expression Program.
    Kalna V; Yang Y; Peghaire CR; Frudd K; Hannah R; Shah AV; Osuna Almagro L; Boyle JJ; Göttgens B; Ferrer J; Randi AM; Birdsey GM
    Circ Res; 2019 Apr; 124(9):1337-1349. PubMed ID: 30892142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
    Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
    Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
    Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
    Udager AM; DeMarzo AM; Shi Y; Hicks JL; Cao X; Siddiqui J; Jiang H; Chinnaiyan AM; Mehra R
    Prostate; 2016 Jun; 76(9):845-53. PubMed ID: 27159573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
    Wasmuth EV; Hoover EA; Antar A; Klinge S; Chen Y; Sawyers CL
    Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8584-8592. PubMed ID: 32220959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic regulation of pancreatic β cell function and gene expression by the SND1 coregulator
    Kanojia S; Davidson RK; Conley JM; Xu J; Osmulski M; Sims EK; Ren H; Spaeth JM
    Islets; 2023 Dec; 15(1):2267725. PubMed ID: 37838950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer.
    Ullman D; Dorn D; Rais-Bahrami S; Gordetsky J
    Urology; 2018 Mar; 113():59-70. PubMed ID: 29225123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.